AHAlex L E Halme

Alex L E Halme

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alex L E Halme has a total of 179 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer

    by Alex L.E. Halme, Matias Posa, Jani Ruotsalainen, Sanna Hallamies, Andreas Carus, Sigurdur Gudjonsson, Heikki Junkkari, Riikka Järvinen, Niko K. Nordlund, Sara Tornberg, et al.

  • Open Access

    Effectiveness of different de-implementation strategies in primary care: systematic review and meta-analysis

    by Aleksi Raudasoja, Sameer Parpia, Jussi M J Mustonen, Robin Vernooij, Petra Falkenbach, Yoshitaka Aoki, Anton Barchuk, Marco H Blanker, Rufus Cartwright, Kathryn Crowder, et al.

    Objective: To evaluate the effectiveness of various de-implementation interventions in primary care, targeting care (treatments or tests) that provides no or limited value for patients (low value care). Design: Systematic review and meta-analysis. Data sources: Medline and Scopus databases, from inception to 10 July 2024. Eligibility criteria for selecting studies: Randomised trials comparing de-implementation interventions with placebo or sham intervention, no intervention, or other de-implementation intervention strategies in primary care. Eligible trials provided information on the use of low value care, total volume of care, appropriate care, and health outcomes. Data extraction and synthesis: Titles, abstracts, and full texts were screened, data were extracted, and risk of bias was assessed independently and in duplicate. Random effects meta-analyses were conducted, and the certainty of evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Results: 13 008 abstracts were screened and 140 were eligible for inclusion in the study. Median follow-up was 287 days (interquartile range 180-365). In 75 (54%) trials the aim was to reduce the use of antibiotics, in 42 (30%) to reduce other drug treatments, in 17 (12%) to reduce imaging, and in 15 (11%) to reduce laboratory testing. The certainty of the evidence was moderate that provider education combined with audit and feedback reduced the use of targeted low value care (odds ratio 0.73, 95% confidence interval (95% CI) 0.63 to 0.84). Provider education (0.86, 95% CI 0.72 to 1.03), audit and feedback (0.82, 0.67 to 1.00), and patient education (0.70, 0.30 to 1.66), and a combination of these strategies (point estimates for odds ratios ranging from 0.57 to 0.64) may reduce the use of targeted low value care (low certainty of evidence for all). Conclusions: The results suggested with moderate certainty of evidence that provider education combined with audit and feedback reduced the use of targeted low value care. Individual strategies may slightly reduce the use of targeted low value care, but achieving a meaningful impact on low value care may require the use of multiple strategies. The results may be useful for patients, clinicians, policy makers, and guideline developers when deciding on future de-implementation strategies and research priorities. Systematic review registration: PROSPERO CRD42023411768.


  • Open Access

    Evidence categories in systematic assessment of cancer overdiagnosis

    by Anton Barchuk, Niko K Nordlund, Alex L E Halme, Kari A O Tikkinen

    The phenomenon of cancer overdiagnosis, the diagnosis of a malignant tumour that, without detection, would never lead to adverse health effects, has been reported for several cancer types in different populations. There has been an increase in studies focused on overdiagnosis, creating an opportunity to synthesise evidence on specific cancer types. However, studies that systematically assess evidence across different research domains remain scarce, with most of them relying on data from studies that already mentioned overdiagnosis as a potential concern. In this review, we consider several evidence categories that are used to systematically assess the presence and magnitude of overdiagnosis, including (1) data from cancer surveillance, (2) studies exploring the ‘true’ prevalence of cancer in the population, (3) studies that explore the use of diagnostics and its effect on incidence and mortality and (4) studies that explore changes and progress in cancer management and its effect on cancer mortality. This article highlights the strengths and weaknesses of different evidence categories, provides examples of studies on different cancer types and discusses how these categories can help synthesise evidence on cancer overdiagnosis.


  • Short- and long-term effects of imatinib in patients hospitalised for COVID-19: A randomised trial

    by Alex Halme, Sanna Laakkonen, Jarno Rutanen, Olli Nevalainen, Marjatta Sinisalo, Saana Horstia, Jussi Mustonen, Negar Pourjamal, Aija Vanhanen, Tuomas Rosberg, et al.

    Background: Earlier evidence has suggested that imatinib may improve 30-day survival in hospitalised COVID-19 patients. Objective: To study the short- and long-term effects of imatinib in hospitalised COVID-19 patients. Methods: We conducted a randomised trial in 15 Finnish hospitals. Participants were randomised between locally available options to receive standard or care (SoC) or SoC with imatinib. Imatinib dosage was 400 mg daily until discharge (max 14 days). Primary outcomes were mortality at 30 days and 1 year. Secondary outcomes included recovery, quality of life and long COVID symptoms at 1 year. We also performed a systematic review and meta-analysis of all randomised trials studying imatinib for 30-day mortality in hospitalised COVID-19 patients. Results: Between August 2021 and March 2023, we randomised 156 patients (103 in 2021, 51 in 2022 and 2 in 2023; 73 in SoC, 83 in imatinib). Among patients on imatinib, 7.2% had died at 30 days and 13.3% at 1 year and among those randomized to SoC 4.1% and 8.3% (adjusted HR 1.09, 95% CI 0.23–5.07). At 1-year, self-reported recovery occurred in 79.0% in imatinib and in 88.3% in SoC (RR 0.91, 0.78-1.06). We found no convincing difference between groups in quality of life or symptoms. Fatigue (24%), sleep issues (19%), and memory problems (17%) frequently bothered patients among 21 potential long COVID symptoms. In the meta-analysis of 4 randomised trials (732 patients), imatinib was associated with a mortality risk ratio of 0.73 (0.32–1.63; low certainty evidence). Conclusions: The evidence raises doubts regarding benefit of imatinib in reducing mortality, improving recovery and preventing long COVID symptoms in hospitalised COVID-19 patients.

  • Open Access

    Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial

    by Alex L.E. Halme, Sanna Laakkonen, Jarno Rutanen, Olli P.O. Nevalainen, Marjatta Sinisalo, Saana Horstia, Jussi M.J. Mustonen, Negar Pourjamal, Aija Vanhanen, Tero Ala-Kokko, et al.


  • Top Cited Papers
    Open Access

    Timing of Major Postoperative Bleeding Among Patients Undergoing Surgery

    by Alex L E Halme, Pavel S Roshanov, Sara V Tornberg, Lauri I Lavikainen, P J Devereaux, Kari A O Tikkinen, VISION Investigators

    More than 300 million patients undergo surgery annually worldwide.1 Bleeding is among the most common surgical complications and is associated with blood transfusion, reintervention, organ injury, and death, as well as increased costs.2-4 Surgical patients often receive prophylactic or therapeutic anticoagulant and antiplatelet medications. Postoperative bleeding risk, which dissipates after surgery, is relevant for decisions about when to use these agents.


  • Fixed-effect Versus Random-effects Models for Meta-analyses: Random-effects Models

    by Alex L.E. Halme, Kristen McAlpine, Alberto Martini


  • Open Access

    Systematic Reviews and Meta-analyses of the Procedure-specific Risks of Thrombosis and Bleeding in General Abdominal, Colorectal, Upper Gastrointestinal, and Hepatopancreatobiliary Surgery

    by Lauri I. Lavikainen, Gordon H. Guyatt, Ville J. Sallinen, Paul J. Karanicolas, Rachel J. Couban, Tino Singh, Yung Lee, Jaana Elberkennou, Riikka Aaltonen, Kaisa Ahopelto, et al.

    Objective: To provide procedure-specific estimates of symptomatic venous thromboembolism (VTE) and major bleeding after abdominal surgery. Background: The use of pharmacological thromboprophylaxis represents a trade-off that depends on VTE and bleeding risks that vary between procedures; their magnitude remains uncertain. Methods: We identified observational studies reporting procedure-specific risks of symptomatic VTE or major bleeding after abdominal surgery, adjusted the reported estimates for thromboprophylaxis and length of follow-up, and estimated cumulative incidence at 4 weeks postsurgery, stratified by VTE risk groups, and rated evidence certainty. Results: After eligibility screening, 285 studies (8,048,635 patients) reporting on 40 general abdominal, 36 colorectal, 15 upper gastrointestinal, and 24 hepatopancreatobiliary surgery procedures proved eligible. Evidence certainty proved generally moderate or low for VTE and low or very low for bleeding requiring reintervention. The risk of VTE varied substantially among procedures: in general abdominal surgery from a median of <0.1% in laparoscopic cholecystectomy to a median of 3.7% in open small bowel resection, in colorectal from 0.3% in minimally invasive sigmoid colectomy to 10.0% in emergency open total proctocolectomy, and in upper gastrointestinal/hepatopancreatobiliary from 0.2% in laparoscopic sleeve gastrectomy to 6.8% in open distal pancreatectomy for cancer. Conclusions: VTE thromboprophylaxis provides net benefit through VTE reduction with a small increase in bleeding in some procedures (eg, open colectomy and open pancreaticoduodenectomy), whereas the opposite is true in others (eg, laparoscopic cholecystectomy and elective groin hernia repairs). In many procedures, thromboembolism and bleeding risks are similar, and decisions depend on individual risk prediction and values and preferences regarding VTE and bleeding.


  • Open Access

    Timing of symptomatic venous thromboembolism after surgery: meta-analysis

    by Tino Singh, Lauri I Lavikainen, Alex L E Halme, Riikka Aaltonen, Arnav Agarwal, Marco H Blanker, Kostiantyn Bolsunovskyi, Rufus Cartwright, Herney García-Perdomo, Rachel Gutschon, et al.

    Background: The timing at which venous thromboembolism (VTE) occurs after major surgery has major implications for the optimal duration of thromboprophylaxis. The aim of this study was to perform a systematic review and meta-analysis of the timing of postoperative VTE up to 4 weeks after surgery. Methods: A systematic search of MEDLINE, Scopus, and CINAHL databases was performed between 1 January 2009 and 1 April 2022. Prospective studies that recruited patients who underwent a surgical procedure and reported at least 20 symptomatic, postoperative VTE events by time were included. Two reviewers independently selected studies according to the eligibility criteria, extracted data, and evaluated risk of bias. Data were analysed with a Poisson regression model, and the GRADE approach was used to rate the certainty of evidence. Results: Some 6258 studies were evaluated, of which 22 (11 general, 5 urological, 4 mixed, and 2 orthopaedic postoperative surgical populations; total 1 864 875 patients and 24 927 VTE events) were eligible. Pooled evidence of moderate certainty showed that 47.1 per cent of the VTE events occurred during the first, 26.9 per cent during the second, 15.8 per cent during the third, and 10.1 per cent during the fourth week after surgery. The timing of VTE was consistent between individual studies. Conclusion: Although nearly half of symptomatic VTE events in first 4 weeks occur during the first postoperative week, a substantial number of events occur several weeks after surgery. These data will inform clinicians and guideline developers about the duration of postoperative thromboprophylaxis.


  • Open Access

    Global practice variation in pharmacologicthromboprophylaxis for general and gynaecologicalsurgery: systematic review

    by Negar Pourjamal, Lauri I Lavikainen, Alex L E Halme, Rufus Cartwright, Kaisa Ahopelto, Gordon H Guyatt, Kari A O Tikkinen

    Dear Editor